Zyla Life Sciences Fresh-Start Adjustment, Increase (Decrease), Cash and Cash Equivalents
Zyla Life Sciences had Fresh-Start Adjustment, Increase (Decrease), Cash and Cash Equivalents of $18.20 million as of 2019-01-31, per its 10-Q filed 2020-05-14.
Discontinued › Notes
us-gaap:FreshStartAdjustmentIncreaseDecreaseCashAndCashEquivalents · last filed 2020-05-14
- 2019-01-31: Fresh-Start Adjustment, Increase (Decrease), Cash and Cash Equivalents $18.20M.
| Period end | Fresh-Start Adjustment, Increase (Decrease), Cash and Cash Equivalents |
|---|---|
| 2019-01-31 | $18.20M 10-Q · filed 2020-05-14 |